Merav Bassan - Dec 11, 2023 Form 4 Insider Report for BiomX Inc. (PHGE)

Role
Chief Development Officer
Signature
/s/ Merav Bassan
Stock symbol
PHGE
Transactions as of
Dec 11, 2023
Transactions value $
$0
Form type
4
Date filed
12/13/2023, 04:43 PM
Previous filing
Oct 31, 2023
Next filing
Jul 15, 2024

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction PHGE Common Stock Options - Right to Buy Disposed to Issuer -47.5K -100% 0 Dec 11, 2023 Common Stock 47.5K $7.02 Direct F1, F2
transaction PHGE Common Stock Options - Right to Buy Award +12.5K 12.5K Dec 11, 2023 Common Stock 12.5K $0.27 Direct F1, F2
transaction PHGE Common Stock Options - Right to Buy Disposed to Issuer -100K -100% 0 Dec 11, 2023 Common Stock 100K $1.41 Direct F3, F4
transaction PHGE Common Stock Options - Right to Buy Award +71.4K 71.4K Dec 11, 2023 Common Stock 71.4K $0.27 Direct F3, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 On December 11, 2023, the Issuer canceled, pursuant to the Issuer's option exchange program, an option for 47,500 shares of the Issuer's common stock granted to the Reporting Person on March 30, 2021. In exchange, the Reporting Person received a replacement option, for 12,500 shares, having an exercise price of $0.2749 per share.
F2 The cancelled option provided for vesting over four years, with 25% of the shares subject to the option vested on March 30, 2022, and the remainder vested in 12 equal quarterly installments over three years. The replacement option vests according to the same vesting schedule applicable to the cancelled option; provided, however, that the replacement option may not be exercised prior to December 11, 2024.
F3 On December 11, 2023, the Issuer canceled, pursuant to the Issuer's option exchange program, an option for 100,000 shares of the Issuer's common stock granted to the Reporting Person on March 29, 2022. In exchange, the Reporting Person received a replacement option, for 71,429 shares, having an exercise price of $0.2749 per share.
F4 The cancelled option provided for vesting over four years, with 25% of the shares subject to the option vested on March 29, 2023, and the remainder vested in 12 equal quarterly installments over three years. The replacement option vests according to the same vesting schedule applicable to the cancelled option; provided, however, that the replacement option may not be exercised prior to December 11, 2024.